---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-006754"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T04:27:27.130603+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director David S. Cunningham to retire from ImmuCell Board after 2023 Annual Meeting

## Summary
- David S. Cunningham notified retirement effective after June 15, 2023 Annual Meeting.
- Retirement not due to any disagreement with the company on operations, policies, or practices.
- No replacement for the departing director has been announced.

## SEC filing metadata
- accession: 0001213900-23-006754
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390023006754/0001213900-23-006754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390023006754/ea172563-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-006754
- JSON: https://secwatch.observer/filing/0001213900-23-006754.json
- Plain text: https://secwatch.observer/filing/0001213900-23-006754.txt

## Key facts
- Executive change
  David S. Cunningham departed as Director at IMMUCELL CORP /DE/.
  - Action: retire
  - Role: Director
  source text: On January 24, 2023, David S. Cunningham notified ImmuCell Corporation (the “Company”) of his intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2023 Annual Meeting to be held on June 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390023006754/0001213900-23-006754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.